Compare Quest Diagnostics Inc (DGX) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while iShares 10 20 Year Treasury Bond ETF trades at $92.23 (market cap $11.02B). The key difference: Quest Diagnostics Inc is far larger — about 2.3× iShares 10 20 Year Treasury Bond ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| DGX | TLH | |
|---|---|---|
Market Cap | $25.48B | $11.02B |
Volume | 941,866 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $105.36 |
52-Week Low | $173.49 | $91.34 |
Typical Hold Time | 56 Days | 60 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $91.45, down 0.12% with a bearish technical outlook. The ETF has seen unusually high trading volume recently, with 2.3 million shares traded on September 30, 2026. Bond market volatility has driven significant price movements as 10-year Treasury yields reached multi-decade highs above 5% before pulling back. The fund maintains regular dividend distributions, with recent payments ranging from $0.36 to $0.38 per share.
The outlook remains challenging amid persistent bond market volatility and expectations of higher-for-longer interest rates. Rising yields pressure bond prices, creating headwinds for TLH, though current levels may attract income-seeking investors. Key risks include further Fed tightening and inflation concerns, while potential catalysts include economic slowdown or Fed policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
